- Home
- SYRE
as 02-21-2025 4:00pm EST
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
| Founded: | 2013 | Country: | United States |
| Employees: | 60 | City: | WALTHAM |
| Market Cap: | 1.3B | IPO Year: | 2016 |
| Target Price: | $51.50 | AVG Volume (30 days): | 550.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.13 - $47.97 | Next Earning Date: | 03-03-2025 |
| Revenue: | N/A | Revenue Growth: | -61.96% |
| Revenue Growth (this year): | 168.62% | Revenue Growth (next year): | 47.61% |
Latest Spyre Therapeutics Inc. News
SYRE Breaking Stock News: Dive into SYRE Ticker-Specific Updates for Smart Investing
PR Newswire
3 days ago
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
PR Newswire
15 days ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
a month ago
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
PR Newswire
2 months ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
2 months ago
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
PR Newswire
3 months ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
3 months ago
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
PR Newswire
3 months ago
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Compare SYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SYRE Spyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.